SYMLIN Drug Patent Profile

Which patents cover Symlin, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Summary for SYMLIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	20
Patent Applications:	680
Drug Prices:	Drug price information for SYMLIN
DailyMed Link:	SYMLIN at DailyMed

See drug prices for SYMLIN

Recent Clinical Trials for SYMLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boston University	Early Phase 1
National Institute on Aging (NIA)	Early Phase 1
H. Lee Moffitt Cancer Center and Research Institute	Early Phase 1

See all SYMLIN clinical trials

Pharmacology for SYMLIN

Drug Class	Amylin Analog
Mechanism of Action	Amylin Agonists

US Patents and Regulatory Information for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007		DISCN	Yes	No
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007		DISCN	Yes	No
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005		DISCN	No	No

Expired US Patents for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007

International Patents for SYMLIN

See the table below for patents covering SYMLIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2828250
European Patent Office	1551436
Australia	714439
Austria	155689
Czech Republic	9600695
Australia	669110
Portugal	717635

Market Dynamics and Financial Trajectory for SYMLIN (Pramlintide)

Last updated: February 20, 2026

What is the current market position of SYMLIN?

SYMLIN (pramlintide) is an injectable adjunct therapy for adults with type 1 and type 2 diabetes who use insulin and do not achieve target blood glucose levels. It was approved by the U.S. Food and Drug Administration (FDA) in 2005. The drug's market presence is limited compared to other antidiabetic agents but maintains steady sales within its niche.

How has the market for pramlintide evolved?

Market Penetration and Adoption

• Patient Population: The estimated U.S. diabetic population exceeds 37 million, with roughly 90-95% diagnosed with type 2 diabetes [1].
• Usage Rates: Estimated prescription volume for SYMLIN remains low, accounting for less than 1% of insulin-treated diabetics [2]. Barriers include injection burden, gastrointestinal side effects, and limited physician familiarity.
• Competitive Landscape: Insulin analogs, GLP-1 receptor agonists, and newer combination products dominate the market, reducing SYMLIN’s share [3].

Market Drivers

• Rising diabetes prevalence globally increases the need for adjunct therapies.
• Recognition of pramlintide’s benefits in weight reduction and postprandial glucose control fuels specific niche use.

Market Limitations

• Poor tolerability due to nausea and injection frequency.
• Cost barriers relative to generic insulins and oral medications.
• Limited awareness among healthcare providers.

What is the financial trajectory for SYMLIN?

Sales Data and Revenue Trends

• Annual Sales: Between 2018 and 2022, U.S. sales hovered around $30 million annually [4].
• Global Market: Limited to North America, with negligible contributions from other markets.
• Market Trends: Sales experienced slight declines in recent years, attributed to switching to newer therapies.

Cost and Pricing Dynamics

• List Price: Approximately $250 per pen pre-filled, with typical treatment courses requiring multiple units weekly.
• Reimbursement: Usually covered by commercial insurance; Medicaid and Medicare coverage less consistent.
• Manufacturing Costs: No public data but estimated to be low given the peptide nature and biosynthetic production.

Future Revenue Potential

• Limited pipeline modifications or next-generation products based on pramlintide.
• Market growth depends on increased adoption, which remains constrained.
• Potential for niche expansion if new formulations reduce side effects or injection frequency.

How might regulatory and market developments impact SYMLIN?

• Regulatory Changes: Approval of combination therapies that include pramlintide may influence prescribing.
• Market Competition: Increasing use of GLP-1 agonists (e.g., semaglutide) addresses similar pathways with oral options or less frequent dosing.
• Patent Status: Patents on SYMLIN have expired, facilitating biosimilar development, which could suppress prices.

What are the strategic implications?

• Opportunities exist in targeting specific patient subsets, such as those requiring weight management.
• Partnering with biotech firms developing implantable or inhaled formulations if innovations emerge.
• Monetization potential remains limited unless new formulations or indications are developed.

Key Takeaways

• SYMLIN has a niche but stable position within diabetes adjunct therapies, with stagnant sales primarily due to market competition and tolerability issues.
• The global and domestic markets for pramlintide are constrained; growth is limited without formulation improvements.
• Revenues hover around $30 million annually, with minimal growth prospects unless clinical or regulatory breakthroughs occur.
• Future expansion depends on changing physician prescribing behaviors, formulation innovation, or emerging competitive therapies.

FAQs

1. Will SYMLIN regain market share?

Unlikely without significant formulation improvements or new clinical evidence. Current market trends favor oral or less invasive alternatives.

2. Are biosimilar versions of pramlintide in development?

No biosimilars have been approved yet. Patent expirations could facilitate biosimilar development, potentially reducing prices.

3. How does SYMLIN compare with GLP-1 receptor agonists?

GLP-1s like semaglutide offer comparable glycemic efficacy with less frequent dosing and oral administration, making SYMLIN less attractive.

4. What markets could provide growth opportunities?

Limited outside North America due to approval and adoption barriers. Potential exists in rapidly developing markets with increasing diabetes prevalence if approved.

5. Is there potential for pipeline innovation?

Potential exists if new delivery methods or combination products emerge. Currently, no advanced formulations are publicly announced.

References

[1] Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.

[2] IQVIA. (2022). Prescription Data for Diabetes Therapeutics.

[3] MarketWatch. (2023). Diabetes Drugs Market Analysis.

[4] EvaluatePharma. (2022). Global Sales Trends for Diabetes Medications.